Delivering extraordinary. Empowering ordinary.
We’re developing novel oral medicines for rare diseases to help patients take part in the everyday activities they enjoy.
Learn MoreStructure-guided Drug Design
We combine traditional cell biology with medicinal chemistry to build synthetic compounds that bind to specific protein targets to fight disease.
See Our ScienceBuilding a Rare Disease Drug Portfolio
We are developing a pipeline of oral drugs for rare diseases, including our next generation kallikrein inhibitor for hereditary angioedema (HAE).
View Our PipelineRecent News
Stay up to date with the latest discoveries, events, and reports from BioCryst.
-
BioCryst Announces Preliminary Full Year 2021 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2022 ORLADEYO Net Revenue and Peak Sales Guidance
-
BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Join Our Team
We are a collection of passionate individuals united by a commitment to scientific excellence and an unwavering focus on the needs of patients.
JOB OPENINGS